Dr Bindu George
First Speaker Afternoon Session
This session will “focus on the clinical aspects of the BLA for the treatment of pediatric patients”
“The FDA generally agrees with the applicants conclusion regarding the safety of remestemcel-L”
“Our presentation will focus on the products efficacy.”
“As discussed this morning the mechanism of action is unclear and it has been difficult to identify and characteristics that correlates with the efficacy outcome in GVHD.”
“Will rely heavily on the chemical trials to provide evidence of efficacy.”
“The efficacy data comes from GVHD study end point day 28 overall response rate.
The results from the study was pretty significant.
Dr George raised many issues with the studies.
Outlined that there were two randomized controlled trials, with data coming from trials which rolled pediatric and adult patient data together and has negative implications for results in examining efficacy for treating pediatric patients.
“We are concerned about the limitations of the study particularly the challenges that may stem from bias”
- Forums
- ASX - By Stock
- MSB
- Ryoncil: ODAC/FDA Meeting Discussion
Ryoncil: ODAC/FDA Meeting Discussion, page-1002
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.31 |
Change
0.040(3.16%) |
Mkt cap ! $1.490B |
Open | High | Low | Value | Volume |
$1.28 | $1.32 | $1.26 | $3.433M | 2.652M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 39558 | $1.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.31 | 21776 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 39558 | 1.300 |
3 | 26433 | 1.295 |
6 | 108207 | 1.290 |
2 | 47468 | 1.285 |
3 | 10889 | 1.280 |
Price($) | Vol. | No. |
---|---|---|
1.310 | 21776 | 3 |
1.315 | 57441 | 5 |
1.320 | 2500 | 1 |
1.325 | 61160 | 4 |
1.330 | 15000 | 2 |
Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |